Therapeutic agent for solid cancer
A novel therapeutic agent for solid cancer capable of hardening the cellular tissue itself of a solid cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue, is disclosed. The therapeutic agent for solid cancer is composed of a liquid composition containing as an active component an ethoxy-containing compound capable of undergoing polycondensation in a cellular tissue. The therapeutic agent for solid cancer is capable of hardening the cellular tissue itself of a solid cancer such as lung cancer to induce death or growth inhibition of cancer cells, causing solidification of the tissue. In conventional therapeutic methods, the risk of metastasis due to spreading of cancer cells through the bloodstream cannot be eliminated. In contrast, this therapeutic agent for solid cancer instantly surrounds cancer cells, so that the risk of metastasis can be largely reduced.
1. A method of killing solid cancer cells or inhibiting growth of solid cancer cells, which comprises injecting an effective amount of a liquid composition containing as an active component an ethoxy-containing compound, which undergoes a polycondensation reaction in a cellular tissue after injection, into a solid cancer, wherein the liquid composition is injected in an amount effective to kill solid cancer cells or inhibit growth of solid cancer cells in said tissue in said patient, and wherein said liquid composition further contains a transition metal ethoxide.
2. The method of claim 1 , wherein said ethoxy-containing compound is an ethoxy-containing silicon compound.
3. The method of claim 2 , wherein said ethoxy-containing silicon compound is an ethoxysilane compound.
4. The method of claim 3 , wherein said ethoxysilane compound is at least one selected from the group consisting of ethyl silicate and condensates thereof, and methyltriethoxysilane and condensates thereof.
5. The method of claim 1 , wherein said therapeutic agent further comprises a cyanoacrylate-based monomer.
6. The method of claim 5 , wherein said cyanoacrylate-based monomer is at least one selected from the group consisting of methyl 2-cyanoacrylate, ethyl 2-cyanoacrylate, iso-propyl 2-cyanoacrylate, n-propyl 2-cyanoacrylate, n-butyl 2-cyanoacrylate, iso-butyl 2-cyanoacrylate, t-butyl 2-cyanoacrylate, hexyl 2-cyanoacrylate, ethoxyethyl 2-cyanoacrylate, octyl 2-cyanoacrylate, and bis(alkylene 2-cyanoacrylate) compounds.
7. The method of claim 2 , wherein said transition metal ethoxide is titanium ethoxide.
8. The method of claim 1 , wherein said therapeutic agent further comprises an X-ray contrast agent or an MRI contrast agent.
9. The method of claim 1 , wherein said solid cancer is lung cancer.
10. The method of claim 5 , wherein said liquid composition is prepared by mixing, immediately before injection, a liquid A comprising said ethoxy-containing compound and said transition metal ethoxide and a liquid B comprising said cyanoacrylate-based monomer.